Enveric Biosciences, Inc. 8-K

What Happened

• Enveric Biosciences, Inc. (ENVB) filed a prospectus supplement on June 9, 2026 to offer an additional $2,425,000 of its common stock under its existing "at-the-market" (ATM) offering agreement with H.C. Wainwright & Co., LLC. The ATM Agreement was originally dated April 9, 2025.
• Prior to this filing, the company has sold an aggregate of $4,483,711.04 of common stock through the Sales Agent under the ATM Agreement. A legal opinion regarding the shares is included as Exhibit 5.1 to the 8-K.

Key Details

• Company: Enveric Biosciences, Inc. (ENVB).
• Event: Prospectus supplement filed to increase available ATM shares by $2,425,000.
• Sales agent: H.C. Wainwright & Co., LLC (ATM Agreement dated April 9, 2025).
• Prior ATM sales: $4,483,711.04 sold through the Sales Agent before this supplement.
• Filing date: June 9, 2026; legal opinion included as Exhibit 5.1.

Why It Matters

• This filing provides Enveric with additional capacity to raise up to $2.425 million of gross proceeds by selling common shares into the market under its existing ATM program, which can be used for general corporate purposes or working capital.
• For investors, ATM offerings increase the company’s ability to access capital on a flexible basis. The issuance of additional shares will increase the number of shares available in the market, which is a material financing activity to monitor alongside the company’s cash needs and dilution metrics.